Your browser doesn't support javascript.
loading
Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant.
Tian, Hong; Kong, Danqing; Li, Yun; Gu, Chengyuan; Yu, Ziqiang; Wang, Zhaoyue; Wu, Depei; Yin, Jie.
Afiliação
  • Tian H; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Kong D; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Li Y; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
  • Gu C; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Yu Z; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Wang Z; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
  • Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Yin J; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Platelets ; 33(6): 951-953, 2022 Aug 18.
Article em En | MEDLINE | ID: mdl-34915800
ABSTRACT
Acquired amegakaryocytic thrombocypenia (AAMT) is an extremely rare hematologic disorder and standard treatment strategy has not been established. We described herein two cases of AAMT who were fully responded to eltrombopag and immunosuppressant. Patient 1 was refractory to steroid, IVIG and recombinant human thrombopoietin (rhTPO). Patient 2 did not respond to high dosage of steroid, IVIG, rhTPO and rituximab. Moreover, his AAMT progressed to aplastic anemia in 5 months. Both patients took eltrombopag and immunosuppressant, then they achieved long-term remission without obvious side effects. Our findings suggest that this combination can be a valuable alternative in AAMT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica / Pirazóis / Benzoatos / Hidrazinas / Imunossupressores Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica / Pirazóis / Benzoatos / Hidrazinas / Imunossupressores Idioma: En Ano de publicação: 2022 Tipo de documento: Article